EUVIMEDEUVIMED entdecken
Crossref

Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome

Ashley Dinh iD, J Michael Savoy, Dimitrios P Kontoyiannis, Koichi Takahashi, Ghayas C Issa, Hagop M Kantarjian iD, Courtney D DiNardo iD, Caitlin R Rausch iD

Cancer · 2024

DOI: 10.1002/cncr.35251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Ashley Dinh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Triazoles, Myelodysplastic Syndromes, Pyridines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ivosidenib is primarily metabolized by CYP3A4; however, it induces CYP450 isozymes, including CYP3A4 and CYP2C9, whereas it inhibits drug transporters, including P‐glycoprotein. Patients with acute myeloid leukemia are at risk of invasive fungal infections, and therefore posaconazole and voriconazole are commonly used in this population. Voriconazole is a substrate of CYP2C9, CYP2C19, and CYP3A4; therefore, concomitant ivosidenib may result in decreased serum concentrations. Although posaconazole is a substrate of P‐glycoprotein, it is metabolized primarily via UDP glucuronidation; thus, the impact of ivosidenib on posaconazole exposure is unknown.

Methods

Patients treated with ivosidenib and concomitant triazole with at least one serum trough level were included. Subtherapeutic levels were defined as posaconazole

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteTriazolesMyelodysplastic SyndromesPyridinesGlycineHumansMaleFemaleMiddle AgedAgedVoriconazoleAged, 80 and overDrug InteractionsAdultAntifungal AgentsAntineoplastic Agents

Stichwörter der Autor:innen

CYP450 inducerQTc prolongationdrug‐drug interactionsivosidenibposaconazolevenetoclaxvoriconazole

Substanzen

TriazolesPyridinesGlycineVoriconazoleAntifungal AgentsAntineoplastic Agentsivosidenibposaconazole

Autor:innen und Institutionen

  • Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Ashley Dinh, Hagop M Kantarjian, Courtney D DiNardo, Caitlin R Rausch

Zitieren

APA

Dinh, A., Savoy, J. M., Kontoyiannis, D. P., Takahashi, K., Issa, G. C., Kantarjian, H. M., DiNardo, C. D., & Rausch, C. R. (2024). Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. https://doi.org/10.1002/cncr.35251

Vancouver

Dinh A, Savoy JM, Kontoyiannis DP, Takahashi K, Issa GC, Kantarjian HM, et al. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2024. doi:10.1002/cncr.35251

BibTeX
@article{Dinh2024,
  author = {Dinh, Ashley and Savoy, J Michael and Kontoyiannis, Dimitrios P and Takahashi, Koichi and Issa, Ghayas C and Kantarjian, Hagop M and DiNardo, Courtney D and Rausch, Caitlin R},
  title = {Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35251}
}
Kostenlos starten →